TBPH logo

TBPH
Theravance Biopharma Inc

1,027
Mkt Cap
$841.91M
Volume
361,592.00
52W High
$21.03
52W Low
$8.32
PE Ratio
8.06
TBPH Fundamentals
Price
$16.35
Prev Close
$16.55
Open
$16.60
50D MA
$16.81
Beta
0.56
Avg. Volume
954,669.35
EPS (Annual)
$2.06
P/B
2.81
Rev/Employee
$1.19M
$723.84
Loading...
Loading...
News
all
press releases
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Theravance Biopharma, Inc. - TBPH
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Theravance Biopharma, Inc. - TBPH INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of...
PR Newswire·2d ago
News Placeholder
More News
News Placeholder
Theravance Biopharma (NASDAQ:TBPH) Given New $17.00 Price Target at B. Riley Financial
B. Riley Financial upped their price objective on Theravance Biopharma from $14.00 to $17.00 and gave the stock a "neutral" rating in a research note on Tuesday...
MarketBeat·4d ago
News Placeholder
Zacks Industry Outlook Highlights Indivior Pharmaceuticals, Catalyst Pharmaceuticals, Theravance Biopharma, Relmada Therapeutics and Avalo Therapeutics
Small drug stocks like Indivior gain traction as biotech recovery strengthens, fueled by innovation, M&A activity, and promising pipeline developments.
Zacks·5d ago
News Placeholder
Theravance Biopharma (NASDAQ:TBPH) Lowered to "Buy" Rating by Wall Street Zen
Wall Street Zen downgraded Theravance Biopharma from a "strong-buy" rating to a "buy" rating in a research report on Monday...
MarketBeat·5d ago
News Placeholder
JPMorgan Chase & Co. Purchases 93,591 Shares of Theravance Biopharma, Inc. $TBPH
JPMorgan Chase & Co. boosted its position in Theravance Biopharma, Inc. (NASDAQ:TBPH - Free Report) by 78.3% in the third quarter, according to its most recent filing with the SEC. The institutional...
MarketBeat·6d ago
News Placeholder
TBPH Investors Have Opportunity to Join Theravance Biopharma, Inc. Fraud Investigation with the Schall Law Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Theravance Biopharma, Inc. (Theravance or the Company) (NASDAQ...
Business Wire·9d ago
News Placeholder
5 Small Drug Stocks to Buy as Sector Recovery Gains Strength
Innovation is at its peak in the Zacks Medical-Drugs industry. INDV, CPRX, TBPH, RLMD and AVTX may prove to be good additions to one's portfolio.
Zacks·9d ago
News Placeholder
TBPH: Reported $22M in Operating Expenses While Advancing Trial Enrollment -- LEVI & KORSINSKY, LLP Investigates
TBPH: Reported $22M in Operating Expenses While Advancing Trial Enrollment -- LEVI & KORSINSKY, LLP Investigates TBPH: Reported $22M in Operating Expenses While Advancing Trial Enrollment -- LEVI...
PR Newswire·10d ago
News Placeholder
Theravance Biopharma, Inc. (NASDAQ:TBPH) Receives Average Rating of "Moderate Buy" from Analysts
Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the eight analysts that are covering the company, MarketBeat reports. Three analysts have rated the stock with a hold rating, three have assigned a buy rating and tw...
MarketBeat·11d ago
News Placeholder
Theravance Biopharma (NASDAQ:TBPH) Raised to "Strong-Buy" at Wall Street Zen
Wall Street Zen raised Theravance Biopharma from a "hold" rating to a "strong-buy" rating in a research note on Sunday...
MarketBeat·13d ago
<
1
2
...
>

Latest TBPH News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.